Prenatal treatment with thyrotrophin releasing hormone to prevent neonatal respiratory distress

Two trials of antenatal thyrotrophin-releasing hormone for fetal maturation: stopping before the due date. Antenatal TRH Trial and the Thyroneth Trial Groups

OBJECTIVES

To determine whether the addition of antenatal thyrotrophin-releasing hormone (TRH) to corticosteroids, given to women at risk of preterm delivery, would decrease the risk of death and severe morbidity associated with prematurity.

DESIGN

Two concurrent multicentre, double blind, randomised, placebo-controlled trials were designed with a common core dataset to be analysed as a single large pragmatic trial.

SETTING

Hospital maternity units.

POPULATIONS

Pregnant women at risk of preterm delivery who had been prescribed a course of corticosteroids to enhance fetal maturation.

INTERVENTIONS

Antenatal administration of TRH 400 microg every eight hours for four doses versus matching placebo.

MAIN OUTCOME MEASURES

Primary: death of the baby or chronic lung disease (defined as oxygen dependency at 28 days after birth). Secondary: other measures of respiratory morbidity, in particular respiratory distress syndrome. Other measures of short term neonatal morbidity including intraventricular haemorrhage and necrotising enterocolitis. Measures of maternal side effects.

RESULTS

The antenatal TRH trial was halted early on the basis of external evidence. Overall a total of 225 women were recruited who delivered 275 babies. The primary outcome of death or chronic lung disease occurred in 33 babies in the TRH group and 43 babies in the placebo group (RR 0.8, 95% CI 0.5-1.2). There were no other differences between the two groups. Stratified analysis did not reveal any differences between the two groups depending on how long before the time of delivery the mother had received the TRH or placebo.

CONCLUSIONS

These trials are too small to provide convincing evidence of the effect of antenatal TRH on neonatal outcome. When added to the existing systematic review and meta-analysis, however, these data should provide evidence on which subsequent practice can be based. The process by which the trials were monitored and stopped is of relevance to future trials.

Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group

BACKGROUND

Pulmonary disease is common in preterm infants, despite antenatal glucocorticoid therapy. The addition of antenatal thyrotropin-releasing hormone therapy has been reported to decrease pulmonary morbidity in these infants.

METHODS

We enrolled 996 women at 13 North American centers who were in preterm labor at <30 weeks' gestation in a double-blind, placebo-controlled, randomized trial of antenatal thyrotropin-releasing hormone, given intravenously in four doses of 400 microg each at eight-hour intervals. The primary outcome was chronic lung disease or death of the infant on or before the 28th day after delivery, and secondary outcomes were respiratory distress syndrome and chronic lung disease or death at 36 weeks' postmenstrual age. Complete data were available for 981 women and their 1134 live-born infants. The 769 infants born at < or = 32 weeks' gestation were defined as the group at risk.

RESULTS

There were no significant differences between the at-risk treatment and placebo groups in mean (+/-SD) birth weight (1109+/-354 vs. 1097+/-355 g), gestational age (27.9+/-2.1 vs. 27.9+/-2.1 weeks), sex, or race. The frequencies of respiratory distress syndrome (66 percent vs. 65 percent), death at 28 days (11 percent vs. 11 percent), chronic lung disease or death at 28 days (45 percent vs. 42 percent) and at 36 weeks (32 percent vs. 34 percent), and other neonatal complications as well as the severity of lung disease were not significantly different in the at-risk treatment and placebo groups. Similarly, there were no differences in outcome between the treatment and placebo groups for the infants born at >32 weeks' gestation.

CONCLUSIONS

In preterm infants at risk for lung disease, antenatal administration of thyrotropin-releasing hormone and glucocorticoid is no more beneficial than glucocorticoid alone.

Effect of antenatal thyrotropin-releasing hormone on uterine contractility, blood pressure, and maternal heart rate

OBJECTIVE

The goal was to study the effects on uterine contractility, blood pressure, and heart rate of thyrotropin-releasing hormone given antenatally in combination with glucocorticoids to accelerate fetal maturation.

STUDY DESIGN

A placebo-controlled, randomized, double-blind study was performed involving 30 women whose pregnancies were followed up at the University Hospital Gasthuisberg in 1994 and 1995.

RESULTS

Thyrotropin-releasing hormone induced a significant mean increase of nearly 6 mm Hg in systolic blood pressure and approximately 5 mm Hg in diastolic blood pressure. The duration of this raise was < 20 minutes. Thyrotropin-releasing hormone had no significant effect on maternal heart rate or uterine contractility: 4.2 +/- 1.6 contractions per hour before versus 4.7 +/- 1.7 contractions per hour after treatment.

CONCLUSIONS

Thyrotropin-releasing hormone induces a small (mean < 6 mm Hg) and brief mean (< 20 minutes) increase in blood pressure but appears to have no clinically detectable effect on uterine contractility.

Maternofetal transfer of thyrotrophin-releasing hormone: effect of concentration and mode of administration

We studied the effect of maternal concentration and mode of administration on transfer rate of TSH-releasing hormone (TRH) in an in vitro model of dually perfused isolated lobule of human term placenta. Varying concentrations (4-40 microg dL(-1)) of TRH were added either to the open maternal circulation to mimic an infusion or as a single bolus dose to the closed maternal circulation. TRH was measured by RIA. Perfusion efficiency in each experiment was determined by using antipyrine and creatinine as diffusable markers. At a concentration equivalent to the usual clinical dose of 400 microg, transplacental transfer of TRH was 0.4 +/- 0.1%, with an fetal/maternal ratio of 0.01 +/- 0.003. Placental clearance rate (y = 0.07x; R2 = 0.97; p < 0.001; n = 28) and uptake of TRH (y = 0.40x; R2 = 0.95; p < 0.001) in the closed experiments increased exponentially with increasing maternal concentration. Placental clearance (y = 0.05x; R2 = 0.99; p < 0.001; n = 30), and uptake of TRH (y = 0.35x; R2 = 0.98; p < 0.01) under steady state also correlated with maternal TRH concentration. For a given concentration, placental clearance and uptake of TRH was comparable whether given as a bolus or an infusion. We conclude that TRH is transferred sparingly across the human term placenta and its transfer rate is a function of the maternal concentration of TRH and not its mode of administration.

Correlates of low thyroxine values at newborn screening among infants born before 32 weeks gestation

We assessed the relation of perinatal factors to severe hypothyroxinemia of prematurity, defined as thyroxine value more than 2.6 standard deviations below the mean for newborns. The 365 survivors of birth before 32 weeks gestation were enrolled in a population-based study of the correlates of neonatal brain injury. In this historical cohort study, mothers were interviewed; perinatal data were abstracted from medical records and neonatal data were collected prospectively. Neonatal thyroxine screening values were retrieved from the New Jersey State Department of Health. Associated with severe hypothyroxinemia were: gestational age 23-27 weeks vs. 31 weeks (OR = 5.1, 95% CI 1.7, 15.2), later age at thyroxine test (OR = 1.6 per day, 95% CI 1.2, 2.1), fraction inspired oxygen at age 24 h > 40% (OR = 3.2, 95% CI 1.1, 8.8), mechanical ventilation (OR = 5.1, 95% CI 1.3, 19.4), diastolic blood pressure < 20 mmHg (OR = 2.3, 95% CI 1.2, 4.3), and > 12 years of maternal education (OR = 0.4, 95% CI 0.22, 1.0). Infants with severe hypothyroxinemia had higher mortality, more days of oxygen supplementation, ventilation and hospitalization and were 11 times more likely to require oxygen supplementation at the postnatal age equivalent to 36 weeks gestational age (odds ratio 10.6, 95% CI 2.3, 48.8). In preterm infants, neonatal thyroxine levels obtained at newborn screening in the first week of life may convey important prognostic information about mortality, morbidity, and the risk for bronchopulmonary dysplasia.

Effect of absent end diastolic flow velocity in the fetal umbilical artery on subsequent outcome

Sixty babies, delivered over a six and a half year period, who had absent end diastolic frequency (AEDF) in the umbilical artery, were studied. Individually matched control pregnancies for gestational age, birth-weight, maternal clinical condition and date of delivery, in whom umbilical artery recordings showed end diastolic frequency, were also studied. Matching was achieved in 36 cases. Neonates from case pregnancies showed no increase in necrotising enterocolitis, intraventricular haemorrhage, pneumothorax, neonatal death or bronchopulmonary dysplasia. However, they were significantly less likely to require ventilation for respiratory distress syndrome (P = 0.02). Although AEDF indicates a fetus under vascular stress, this finding alone will include a spectrum of response in the baby, from the well compensated to the irreversibly damaged. Delivery at different points in the deteriorating fetal environment may explain discrepant study results. This intrauterine stress, by increasing fetal corticosteroid and thyroid hormones, may account for enhanced lung maturity. Predictions of neonatal course need to be based on more comprehensive awareness of fetal status.

[Prenatal corticotherapy and acceleration of fetal maturation. II. Results of clinical applications]

Numerous subsequent controlled trials and recent meta-analysis have confirmed the efficiency of antenatal glucocorticoid therapy in reducing both the incidence of respiratory distress syndrome (RDS) and perinatal mortality. Moreover, antenatal glucocorticoid administration reduces the odds of several severe complications relating to immaturity: intraventricular hemorrhage (IVH), ductus arteriosus patency, necrotising enterocolitis, and hemodynamic failure. Exogenous surfactant therapy has not ruled out the benefits of corticosteroids: on the contrary, a synergic effect is obtained when both antenatal and postnatal therapeutic approaches are combined. Very premature infants may also take advantage of the hormonal treatment: in this population, RDS occurrence, IVH incidence and perinatal mortality are also reduced. Unfortunately, despite convincing evidence, the incidence of antenatal steroids therapy has not yet achieved the optimal and desirable level. Obstetricians and pediatricians must be encouraged to ensure high maternal exposure to steroids when preterm delivery is likely to occur.

Fetal hypopituitarism: perinatal endocrine and morphological studies in two cases

We report two infants with congenital absence of the anterior pituitary gland, documented by magnetic resonance imaging (MRI) or autopsy. In cord plasma obtained at birth from both infants, prolactin (PRL), pituitary growth hormone (hGH), placental growth hormone (hPGH) and thyrotropin (TSH) were undetectable; cortisol was low; thyroxine (T4) was 31 nmol/l in one infant and 85 nmol/l in the other infant who had been treated prenatally with intra-amniotic L-T4 administration. In maternal plasma at birth, PRL, hPGH and T4 were normal and hGH was undetectable. These observations suggest that plasma hGH and PRL in the fetus are exclusively of fetal pituitary origin, hPGH is secreted into the maternal circulation and is not transferred to the fetus and fetal growth can be normal in the absence of hGH, hPGH and PRL in fetal plasma.